2.20

1.38% 0.03

Ensysce Biosciences Inc (ENSC)

Overview News Price History Financials Discussions Forecast Stock Split

Ensysce Biosciences Inc stock is traded at $2.20, with a volume of 30,949. It is up +1.38% in the last 24 hours and down -40.05% over the past month. Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Previous Close:

$2.17

Open:

$2.17

24h Volume:

30,949

Relative Volume:

0.02

Market Cap:

$5.21M

Revenue:

Net Income/Loss:

$-11.28M

P/E Ratio:

-0.7309

EPS:

-3.01

Net Cash Flow:

$-9.78M

1W Performance:

-5.98%

1M Performance:

-40.05%

6M Performance:

-65.89%

1Y Performance:

-75.09%

1-Day Range:

$2.1081

$2.22

1-Week Range:

$2.0881

$2.6299

52-Week Range:

$1.62

$14.67

Ensysce Biosciences Inc Stock (ENSC) Company Profile

Name

Ensysce Biosciences Inc

Sector

Healthcare (1173)

Industry

Biotechnology (666)

Phone

(858) 263-4196

Address

7946 IVANHOE AVENUE, LA JOLLA

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ENSC's Discussions on Twitter

Compare ENSC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENSC Ensysce Biosciences Inc	2.20	5.55M	0	-11.28M	-9.78M	-3.01
ONC Beigene Ltd Adr	241.43	27.03B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	436.00	112.64B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.335	40.86M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	588.34	64.17B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	75.06	6.07B	0	-153.72M	-103.81M	-2.00

Ensysce Biosciences Inc Stock (ENSC) Latest News

May 19, 2025

Where are the Opportunities in (ENSC) - news.stocktradersdaily.com

May 19, 2025

May 17, 2025

Zacks Small Cap Analysts Boost Earnings Estimates for ENSC - Defense World

May 17, 2025

May 16, 2025

Ensysce Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 15, 2025

Ensysce Biosciences Advances in Pain Relief Innovation - TipRanks

May 15, 2025

May 13, 2025

Revolutionary Opioid Treatment Proves Overdose-Proof in Clinical Trials, Secures Key Patent - Stock Titan

May 13, 2025

May 12, 2025

Ensysce Biosciences Bolsters Management Team with Regulatory Expert - Stock Titan

May 12, 2025

May 11, 2025

Head-To-Head Contrast: CV Sciences (OTCMKTS:CVSI) and Ensysce Biosciences (NASDAQ:ENSC) - Defense World

May 11, 2025

May 08, 2025

Ensysce Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire

Apr 25, 2025

Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules - ACCESS Newswire

Apr 25, 2025